Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia

British Journal of Pharmacology
Y NodaT Nabeshima

Abstract

1. Immobility induced by forced swimming is well known as an animal model of depression. To develop an animal model for the negative symptoms of schizophrenia, in particular the depressive symptoms, the effect of phencyclidine (PCP) on immobility in the forced swimming test was investigated in mice, since PCP produces such negative symptoms in humans. 2. Repeated treatment with PCP (10 mg kg-1 day-1, s.c., once a day for 14 days) prolonged the immobility time in the forced swimming test 24 h after the final injection compared with saline treatment; the effect was not obtained by single or 5 treatments with PCP (10 mg kg-1, s.c.), or by repeated treatment with methamphetamine (0.5 and 1 mg kg-1 day-1, s.c., once a day for 14 days). 3. The enhancing effect of PCP (10 mg kg-1 day-1, s.c.) on the immobility persisted for at least 21 days after the withdrawal of the drug. 4. Haloperidol (0.3 and 1 mg kg-1, p.o.), ritanserin (3 and 10 mg kg-1, p.o.), risperidone (0.1-1 mg kg-1, p.o.), and clozapine (3 and 10 mg kg-1, p.o.) failed to attenuate the immobility induced by the forced swimming in mice repeatedly treated with saline when the drugs were administered 1 h before the forced swimming test. However, ritanserin (30 mg kg-1) and cl...Continue Reading

References

Feb 15, 1978·European Journal of Pharmacology·R D PorsoltM Jalfre
Jan 1, 1976·Clinical Toxicology·P V Luisada, B I Brown
Oct 11, 1975·The American Journal of Psychiatry·J M Rainey, M K Crowder
Jan 11, 1976·The American Journal of Psychiatry·T H McGlashan, W T Carpenter
Mar 1, 1992·Trends in Pharmacological Sciences·G P Reynolds
Sep 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·V PeraltaM J Cuesta
Oct 1, 1992·Seminars in Nuclear Medicine·N D Volkow, J S Fowler
Mar 1, 1992·Archives of General Psychiatry·W S Fenton, T H McGlashan
Apr 1, 1992·Physiology & Behavior·H H Van DijkenF J Tilders
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 1, 1991·Schizophrenia Bulletin·H Y Meltzer
Dec 1, 1991·The Journal of Nervous and Mental Disease·F B DickersonJ J Boronow
Nov 5, 1991·European Journal of Pharmacology·V S Murua, V A Molina
Jan 1, 1991·European Archives of Psychiatry and Clinical Neuroscience·G A Wiesbeck, K L Taeschner
Jan 1, 1990·Modern Problems of Pharmacopsychiatry·P BoyerA J Puech
Jan 1, 1990·The Journal of Neuropsychiatry and Clinical Neurosciences·D C Javitt, S R Zukin
Feb 1, 1991·Fortschritte der Neurologie-Psychiatrie·F Kukla, R Gold
Jan 1, 1990·Modern Problems of Pharmacopsychiatry·N C Andreasen
Jul 31, 1989·Neuroscience Letters·T NabeshimaK C Rice
Apr 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R BarnesM Patel
Jan 1, 1987·Synapse·P C ContrerasT L O'Donohue
Jan 1, 1988·Synapse·P C ContrerasC C Lair
Jul 9, 1987·European Journal of Pharmacology·T NabeshimaT Kameyama
Oct 18, 1988·European Journal of Pharmacology·B L LargentS H Snyder
Feb 11, 1986·European Journal of Pharmacology·P C ContrerasT L O'Donohue
Jan 1, 1988·Schizophrenia Bulletin·A BleichH M van Praag
Jan 1, 1985·Psychopharmacology·D L CeulemansP A Janssen
Feb 12, 1985·European Journal of Pharmacology·T NabeshimaT Kameyama
Nov 1, 1974·Behavioral Biology·H F Harlow, S J Suomi
Nov 1, 1972·Comprehensive Psychiatry·M J SternS M Sonnenberg
Jul 1, 1981·Archives of General Psychiatry·A Knights, S R Hirsch
Sep 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S W Tam, L Cook
Sep 1, 1984·Pharmacology, Biochemistry, and Behavior·T NabeshimaT Kameyama
Jan 1, 1981·Neuroscience and Biobehavioral Reviews·R J KatzB J Carroll
Oct 1, 1994·Japanese Journal of Pharmacology·K KitaichiT Nabeshima

❮ Previous
Next ❯

Citations

Aug 24, 2011·Psychopharmacology·Chisato WakabayashiHiroshi Kunugi
Dec 8, 2011·Psychopharmacology·Barbara LangenNorbert Hoefgen
Apr 16, 2004·Behavioural Brain Research·Eun-Joo ShinHyoung-Chun Kim
May 17, 2005·Neuroscience and Biobehavioral Reviews·Alasdair M Barr, Athina Markou
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sevda Bulduk, Resit Canbeyli
Jul 19, 2000·Pharmacology, Biochemistry, and Behavior·S M TurgeonW W Graves
Jun 19, 1998·Pharmacology, Biochemistry, and Behavior·S M TurgeonM A Heller
Jun 6, 2003·Neuroscience and Biobehavioral Reviews·Albert Hung Choy Wong, Hubert H M Van Tol
Mar 2, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jean-Philippe RénéricLuis Stinus
Mar 31, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul R LeeJames I Koenig
Dec 17, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tadashi IshibashiHiroshi Nakamura
Nov 10, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ramy E AbdelhamidAlice A Larson
Aug 6, 2002·Journal of Neuroimmunology·Boris SakicHenry Szechtman
Dec 18, 2015·The Journal of Pharmacology and Experimental Therapeutics·Eri ShiraishiHaruhide Kimura
Nov 21, 2014·Journal of Pharmacological Sciences·Yoshiaki Miyamoto, Atsumi Nitta
Mar 4, 2011·Medical Hypotheses·Edward C Lauterbach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here